ABUS Historical PE Ratio image   This ABUS PE ratio history page last updated 5/23/2022
ABUS Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q1 2022
5/5/2022
2.55-0.11-0.44NA
Q4 2021
3/3/2022
2.95-0.15-0.60NA
Q3 2021
11/4/2021
3.88-0.24-0.96NA
Q2 2021
8/5/2021
3.04-0.23-0.92NA
Q1 2021
5/5/2021
2.96-0.21-0.84NA
Q4 2020
3/4/2021
3.14-0.23-0.92NA
Q3 2020
11/5/2020
2.87-0.27-1.08NA
Q2 2020
8/7/2020
3.80-0.25-1.00NA
Q1 2020
5/11/2020
1.44-0.25-1.00NA
Q4 2019
3/5/2020
3.00-0.46-1.84NA
Q3 2019
11/6/2019
1.45-0.73-2.92NA
Q2 2019
8/5/2019
1.60-0.46-1.84NA
Q1 2019
5/6/2019
2.63-0.47-1.88NA
Q4 2018
3/7/2019
4.02-0.37-1.48NA
Q3 2018
11/7/2018
4.95-0.30-1.20NA
Q2 2018
8/2/2018
12.35-0.44-1.76NA
Q1 2018
5/3/2018
5.85-0.36-1.44NA
Q4 2017
3/14/2018
5.65-0.35-1.40NA
Q3 2017
11/2/2017
5.45-0.17-0.68NA
Q2 2017
8/3/2017
3.40-0.28-1.12NA
Q1 2017
5/4/2017
3.35-0.29-1.16NA
Q4 2016
3/21/2017
3.20-0.38-1.52NA
Q3 2016
11/3/2016
3.05-0.31-1.24NA
Q2 2016
8/4/2016
4.37-0.35-1.40NA
Q1 2016
5/4/2016
4.64-0.19-0.76NA
Q4 2015
3/9/2016
3.88-0.07-0.28NA
Q3 2015
11/5/2015
5.77-0.31-1.24NA
Q2 2015
8/5/2015
10.33-0.20-0.80NA
Q1 2015
5/6/2015
14.42-0.36-1.44NA
Q4 2014
3/9/2015
17.85-0.27-1.08NA
Q3 2014
11/14/2014
16.41-0.39-1.56NA
Q2 2014
8/13/2014
18.60-0.31-1.24NA
Q1 2014
5/14/2014
12.02-0.93-3.72NA
Q4 2013
3/6/2014
26.26-0.10-0.40NA
Q3 2013
11/13/2013
7.67-0.42-1.68NA
Q2 2013
8/12/2013
5.63-0.22-0.88NA
Q1 2013
5/14/2013
4.89-0.18-0.72NA
Q4 2012
3/27/2013
4.662.8111.240.4
Q3 2012
11/13/2012
5.60-0.25-1.00NA
ABUS PE History Chart
PeriodPriceGAAPTTMPE
Q1 2022
5/5/2022
2.55-0.11-0.73NA
Q4 2021
3/3/2022
2.95-0.15-0.83NA
Q3 2021
11/4/2021
3.88-0.24-0.91NA
Q2 2021
8/5/2021
3.04-0.23-0.94NA
Q1 2021
5/5/2021
2.96-0.21-0.96NA
Q4 2020
3/4/2021
3.14-0.23-1.00NA
Q3 2020
11/5/2020
2.87-0.27-1.23NA
Q2 2020
8/7/2020
3.80-0.25-1.69NA
Q1 2020
5/11/2020
1.44-0.25-1.90NA
Q4 2019
3/5/2020
3.00-0.46-2.12NA
Q3 2019
11/6/2019
1.45-0.73-2.03NA
Q2 2019
8/5/2019
1.60-0.46-1.60NA
Q1 2019
5/6/2019
2.63-0.47-1.58NA
Q4 2018
3/7/2019
4.02-0.37-1.47NA
Q3 2018
11/7/2018
4.95-0.30-1.45NA
Q2 2018
8/2/2018
12.35-0.44-1.32NA
Q1 2018
5/3/2018
5.85-0.36-1.16NA
Q4 2017
3/14/2018
5.65-0.35-1.09NA
Q3 2017
11/2/2017
5.45-0.17-1.12NA
Q2 2017
8/3/2017
3.40-0.28-1.26NA
Q1 2017
5/4/2017
3.35-0.29-1.33NA
Q4 2016
3/21/2017
3.20-0.38-1.23NA
Q3 2016
11/3/2016
3.05-0.31-0.92NA
Q2 2016
8/4/2016
4.37-0.35-0.92NA
Q1 2016
5/4/2016
4.64-0.19-0.77NA
Q4 2015
3/9/2016
3.88-0.07-0.94NA
Q3 2015
11/5/2015
5.77-0.31-1.14NA
Q2 2015
8/5/2015
10.33-0.20-1.22NA
Q1 2015
5/6/2015
14.42-0.36-1.33NA
Q4 2014
3/9/2015
17.85-0.27-1.90NA
Q3 2014
11/14/2014
16.41-0.39-1.73NA
Q2 2014
8/13/2014
18.60-0.31-1.76NA
Q1 2014
5/14/2014
12.02-0.93-1.67NA
Q4 2013
3/6/2014
26.26-0.10-0.92NA
Q3 2013
11/13/2013
7.67-0.421.993.9
Q2 2013
8/12/2013
5.63-0.222.162.6
Q1 2013
5/14/2013
4.89-0.18NANA
Q4 2012
3/27/2013
4.662.81NANA
Q3 2012
11/13/2012
5.60-0.25NANA
Quotes delayed 20 minutes

Email EnvelopeFree ABUS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Arbutus Biopharma (ABUS) is categorized under the Miscellaneous sector; to help you further research PE history across stocks, below are some other companies in the same sector:

ACHR PE Ratio History
ACN PE Ratio History
ADNT PE Ratio History
ADTH PE Ratio History
AEVA PE Ratio History
AFMD PE Ratio History
ALIT PE Ratio History
ALLE PE Ratio History
AMPS PE Ratio History
APTV PE Ratio History
How should the ABUS historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Arbutus Biopharma. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this ABUS Historical PE Ratio page.

What is the average historical PE for ABUS based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The ABUS historical PE ratio using the annualized quarterly earnings method works out to 0.4.

What is the average historical PE for ABUS based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The ABUS historical PE ratio using the TTM earnings method works out to 3.2.

On this page we presented the ABUS Historical PE Ratio information for Arbutus Biopharma' stock. The average ABUS historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 0.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ABUS historical PE based on this TTM earnings result method is 3.2. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ABUS historical PE result, against the recent PE: when this page was posted on 5/23/2022, the most recent closing price for ABUS had been 2.40, and the most recent quarterly earnings result, annualized, was 11.24. Meanwhile, the most recent TTM earnings summed to 1.99. From these numbers, we calculate the recent ABUS PE on 5/23/2022 based on annualized quarterly EPS was 0.2. Based on ABUS's history, that recent PE is low relative to the historical average, with the recent PE 50.0% lower than the historical average PE across our data set for Arbutus Biopharma. Looking at the recent ABUS PE on 5/23/2022 based on TTM EPS, we calculate the ratio at 1.2. Based on ABUS's history, that recent PE is low relative to the historical average, with the recent PE 62.5% lower than the average PE across our Arbutus Biopharma data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on ABUS or any other given stock, valuation analysis for ABUS can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Arbutus Biopharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ABUS. Thanks for visiting, and the next time you need to research ABUS Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Institutional Holders of SOLY, Funds Holding HDGE, Institutional Holders of PTEN.

 

ABUS Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.